Net Cash Provided by (Used in) Financing Activities in USD of GT Biopharma, Inc. from 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
GT Biopharma, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2010 to Q1 2025.
  • GT Biopharma, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $616K.
  • GT Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $2.98M, a 52.5% decline from 2023.
  • GT Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $6.27M.
  • GT Biopharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$224K, a 101% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)

GT Biopharma, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $616K 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q1 2023 $6.27M 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024
Q1 2021 $25.9M +$25.7M +12871% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022
Q1 2020 $200K -$752K -79% 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021
Q1 2019 $952K -$5.57M -85.4% 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q1 2018 $6.52M +$5.66M +653% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2019
Q1 2017 $866K +$716K +477% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018
Q1 2016 $150K -$2.2M -93.6% 01 Jan 2016 31 Mar 2016 10-Q/A 28 Feb 2018
Q1 2015 $2.35M +$2.3M +4600% 01 Jan 2015 31 Mar 2015 10-Q/A 28 Feb 2018
Q1 2014 $50K +$49K 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015
Q1 2013 $1K* -$219K 01 Jan 2013 31 Mar 2013 10-Q 08 Jan 2015
Q1 2012 $220K +$126K +134% 01 Jan 2012 31 Mar 2012 10-Q 10 Dec 2014
Q1 2011 $94K 01 Jan 2011 31 Mar 2011 10-Q 21 May 2012

GT Biopharma, Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $2.98M -$3.29M -52.5% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025
2023 $6.27M +$6.49M 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025
2022 -$224K -$42.5M -101% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024
2021 $42.3M +$29.8M +238% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 $12.5M +$9.1M +266% 01 Jan 2020 31 Dec 2020 10-K 28 Mar 2022
2019 $3.43M -$6.77M -66.4% 01 Jan 2019 31 Dec 2019 10-K 16 Apr 2021
2018 $10.2M +$4.21M +70.2% 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020
2017 $5.99M +$4.09M +215% 01 Jan 2017 31 Dec 2017 10-K 29 Mar 2019
2016 $1.9M -$1.95M -50.6% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2018
2015 $3.85M +$1.27M +49.1% 01 Jan 2015 31 Dec 2015 10-K/A 28 Feb 2018
2014 $2.58M +$2.16M +508% 01 Jan 2014 31 Dec 2014 10-K/A 28 Feb 2018
2013 $425K -$505K -54.3% 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2015
2012 $930K -$71K -7.09% 01 Jan 2012 31 Dec 2012 10-K 08 Jan 2015
2011 $1M +$705K +238% 01 Jan 2011 31 Dec 2011 10-K 18 Nov 2014
2010 $296K 01 Jan 2010 31 Dec 2010 10-K 16 Apr 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.